TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1955630
Drug: Budesonide (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (one dose before exercise)
Study: 28976863
Drug: Obinutuzumab-based chemotherapy
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab-based chemotherapy
Study: 28976863
Drug: Rituximab-based chemotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-based chemotherapy
Study: 23829882
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (thrust or nonthrust manipulation) with a standardized exercise program for 2 treatment sessions
Study: 23829882
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (thrust or nonthrust manipulation)
Study: 18345342
Drug: Gastrocnemius stretching
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrocnemius stretching exercise (2 times daily for 3 weeks) with subtalar joint in supination or pronation
Study: 12728166
Drug: Fluticasone aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone aqueous nasal spray (50 micro g) into each nostril twice daily
Study: 8864314
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 7195 aerosol 2 mg
Study: 8864314
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 7195 aerosol 4 mg
Study: 6135830
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml HDCSV intradermally at each of eight sites
Study: 6135830
Drug: Intramuscular (im)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (im) administration of HDCSV
Study: 6135830
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine given subcutaneously (sc)
Study: 6135830
Drug: Semple vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semple vaccine
Study: 3755650
Drug: piperazinedione at
Normalized name: 2,5-piperazinedione
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperazinedione at a dose of 9 mg/m2 iv every 3 weeks
Study: 24401928
Drug: NPLD (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPLD (50 mg/m² every 3 weeks for six cycles) + trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly) + paclitaxel (80 mg/m² weekly)
Study: 24401928
Drug: Trastuzumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab + paclitaxel (same doses as above)
Study: 14676103
Drug: Intravenous mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mesna regimen (20% ifosfamide dose) at 0, 4, and 8 h
Study: 14676103
Drug: Intravenous/oral mesna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous/oral mesna regimen (i.v. mesna at 0 h, oral tablet at 2 and 6 h)
Study: 2031511
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg q.i.d.)
Study: 2031511
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg q.i.d.)
Study: 2031511
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets q.i.d.)
Study: 27454266
Drug: TP injections
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TP injections using particulate steroids mixed with a local anesthetic
Study: 22328340
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (ADHD without MPH)
Study: 16385874
Drug: CCR5 antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CCR5 antagonists (experimental medications)
Study: 16385874
Drug: Enfuvirtide (previously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (previously approved medication)
Study: 16385874
Drug: Other mechanisms
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other mechanisms of action (attachment inhibitors, CXCR4 inhibitors)
Study: 2892336
Drug: SMS 201‐995
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS 201‐995 plus injection sclerotherapy
Study: 31431112
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin I assay with sex-specific thresholds (>16 ng/L women, >34 ng/L men)
Study: 28390493
Drug: Cognitive‐behavioral conjoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral conjoint therapy (CBCT) for PTSD
Study: 17165348
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 0.02 mg/kg
Study: 29683914
Drug: Daily undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily undulating periodization (UP)
Study: 21636319
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin treatment guided by EMG
Study: 21636319
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin treatment based on clinical judgement alone
Study: 7992901
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (0.4 mg.kg-1 bolus followed by 30 micrograms.kg-1.min-1)
Study: 7992901
Drug: Clonidine (3-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (3-4 micrograms.kg-1 oral)
Study: 7992901
Drug: Nasal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal lidocaine (2 ml of 4% spray)
Study: 2608700
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg pessary
Study: 4219401
Drug: 1.5% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% amino acid solution with 10% carbohydrates (sorbitol, xylitol)
Study: 4219401
Drug: Conventional basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional basic electrolyte solution
Study: 24127346
Drug: Intravenous aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous aflibercept 2 mg/kg
Study: 24127346
Drug: Intravenous aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous aflibercept 4 mg/kg
Study: 15573736
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride at 1-2 mg/kg
Study: 9849445
Drug: Erythropoietin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (200 U/kg body weight daily)
Study: 2048592
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms ethinyl estradiol and 1.0 mg norethindrone
Study: 2048592
Drug: 35 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 micrograms ethinyl estradiol and 1.0 mg norethindrone
Study: 2048592
Drug: Type O
Normalized name: Yersinia enterocolitica type O:3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type O women using the highest estrogen dose preparation (50 micrograms)
Study: 2048592
Drug: Non-type O
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-type O women using the lowest progestin dose preparation (0.5 mg)
Study: 25212456
Drug: Deferasirox treatment
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox treatment for iron overload
Study: 12092634
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E)
Study: 9632125
Drug: Behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural group therapy
Study: 8291731
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg intravenous (2 ml) ketorolac, followed by 30 mg intravenously (in saline 20 ml) over 30 min every 6 h
Study: 8291731
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml intravenous saline, followed by saline 20 ml intravenously over 30 min every 6 h
Study: 23744953
Drug: Subcostal TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcostal TAP block (group TAP) with 20 mL of 0.375% ropivacaine
Study: 23744953
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (group EA) with 8 mL of 0.25% ropivacaine before induction and maintained with 5 mL/h of 0.25% ropivacaine
Study: 14559046
Drug: Manual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual treatment (MT group)
Study: 10762020
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tamoxifen and Fenretinide (4-HPR)
Study: 8955967
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 0.025 mg.kg‐1
Study: 8955967
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 0.050 mg.kg‐1
Study: 8955967
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 0.050-0.150 mg.kg‐1
Study: 27823869
Drug: Mavoglurant 25
Normalized name: Mavoglurant
DrugBank: Mavoglurant (DB13004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavoglurant 25 mg
Study: 27823869
Drug: Mavoglurant 50
Normalized name: Mavoglurant
DrugBank: Mavoglurant (DB13004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavoglurant 50 mg
Study: 27823869
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (oral)
Study: 22963754
Drug: 1% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tetracaine gel
Study: 22963754
Drug: 1% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tetracaine solution
Study: 21064010
Drug: Procaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine infusion (1% solution, 8 ml/h, 1.92 g/24 h)
Study: 21064010
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (0.9% saline solution)
Study: 14745070
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (1,500 mg daily)
Study: 12193977
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg warfarin daily
Study: 12193977
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg warfarin daily
Study: 12193977
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg warfarin daily
Study: 12193977
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg phenprocoumon daily
Study: 12193977
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg phenprocoumon daily
Study: 2594898
Drug: Diazepam (DZ)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZ) 40 or 80 mg
Study: 2594898
Drug: Triazolam (TZ)
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triazolam (TZ) 1.0 or 2.0 mg
Study: 28474866
Drug: Gymnastics training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gymnastics training (G)
Study: 27680484
Drug: Fentanyl 30
Normalized name: fentaNYL 300 mcg oral lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 30 μg/mL
Study: 27680484
Drug: Fentanyl 15
Normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 15 μg/mL
Study: 23523674
Drug: Immediate pegylated
Normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate pegylated interferon alfa-2b treatment for 24 weeks
Study: 23523674
Drug: Delayed pegylated
Normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed pegylated interferon alfa-2b plus ribavirin treatment starting 12 weeks after randomisation if HCV RNA remained positive
Study: 23523674
Drug: Delayed pegylated
Normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed pegylated interferon alfa-2b plus ribavirin treatment
Study: 23523674
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (symptomatic or asymptomatic)
Study: 23523674
Drug: Asymptomatic patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymptomatic patients receiving immediate treatment
Study: 9538651
Drug: Streptokinase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase treatment (Group 2)
Study: 9538651
Drug: No streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: No streptokinase treatment (Group 1)
Study: 1493087
Drug: Trimethoprim (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (150 mg)
Study: 1493087
Drug: Trimethoprim-sulphamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulphamethoxazole (160 and 800 mg)
Study: 3895099
Drug: Intensive cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cyclic therapy (using drugs like AMSA, 5-AZA, and HD-araC) during remission induction.
Study: 3895099
Drug: Maintenance arm
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance arm I (specific drugs not detailed).
Study: 3895099
Drug: Maintenance arm
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance arm II (specific drugs not detailed).
Study: 31012052
Drug: Red blood
Normalized name: Red blood cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red blood cell (RBC) transfusion at a hemoglobin level of ≤ 70 g·L–1 in the acute phase of care
Study: 31012052
Drug: Red blood
Normalized name: Red blood cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red blood cell (RBC) transfusion at a hemoglobin level of ≤ 70 g·L–1 in the plateau phase of care
Study: 27629292
Drug: Once-monthly paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once-monthly paliperidone palmitate (PP)
Study: 27629292
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral antipsychotics (COAs)
Study: 27629292
Drug: Atypical oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical oral antipsychotics (AOAs)
Study: 27629292
Drug: Oral paliperidone/risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paliperidone/risperidone
Study: 16552830
Drug: continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuation of preceding Kampo prescription
Study: 10821985
Drug: Oral cotinine
Normalized name: Chinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cotinine
Study: 1311794
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 B‐estradiol (TTS 50; 50 mcg/day)
Study: 1311794
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 B‐estradiol (TTS 50; 50 mcg/day) + Vaginal progesterone (P4; 100 mg twice daily)
Study: 25421475
Drug: ACT-451840 200
Normalized name: ACT-451840
DrugBank: ACT-451840 (DB13054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-451840 200 mg
Study: 25421475
Drug: ACT-451840 500
Normalized name: ACT-451840
DrugBank: ACT-451840 (DB13054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-451840 500 mg
Study: 25421475
Drug: ACT-451840 500
Normalized name: ACT-451840
DrugBank: ACT-451840 (DB13054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-451840 500 mg with food
Study: 25421475
Drug: ACT-451840 200
Normalized name: ACT-451840
DrugBank: ACT-451840 (DB13054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-451840 200 mg and 500 mg
Study: 22526973
Drug: Laser dissection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser dissection (L)
Study: 16837887
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (CEE) 0.625 mg daily and 2.5 mg of medroxyprogesterone acetate daily
Study: 16837887
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (TE2) 50 mcg twice weekly and 2.5 mg of medroxyprogesterone acetate daily
Study: 14992985
Drug: Pramipexole (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (mean maximum dose=1.7 mg/day, SD=1.3)
Study: 11376503
Drug: Microstream capnometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microstream capnometer (NBP‐75, Nellcor Puritan Bennett) with an aspiration flow rate of 30 ml.min‐1
Study: 11376503
Drug: Conventional sidestream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sidestream capnometer with a 200 ml.min‐1 aspiration flow rate
Study: 8111816
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day nifedipine
Study: 8111816
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day nifedipine
Study: 8111816
Drug: 90 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/day nifedipine
Study: 22488107
Drug: Pentosan Polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan Polysulfate Sodium (PPS), single oral dose
Study: 22488107
Drug: Pentosan Polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan Polysulfate Sodium (PPS), daily oral doses for 8 weeks
Study: 22488107
Drug: Heparin, lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin, lower doses than used for anticoagulation
Study: 20829712
Drug: ACEi (enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEi (enalapril 20 mg/day) during high salt (200 mmol Na/day)
Study: 20829712
Drug: ACEi (enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEi (enalapril 20 mg/day) during low salt (50 mmol Na/day)
Study: 16988909
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g protein (14 g whey and casein protein, 6 g free amino acids)
Study: 16988909
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g dextrose placebo
Study: 10435264
Drug: Alcohol self-administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol self-administration study with naltrexone
Study: 7381649
Drug: 43 microgram
Normalized name: gonadorelin
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 43 microgram HA vaccine
Study: 7381649
Drug: 10 microgram
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microgram HA vaccine
Study: 7381649
Drug: 4 microgram
Normalized name: Paricalcitol 4 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 microgram HA vaccine
Study: 17944013
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of epinephrine (5 mg each)
Study: 17944013
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of epinephrine (1 mg each)
Study: 15172463
Drug: Intracoronary beta-radiation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary beta-radiation therapy (ICR)
Study: 7574814
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy combined with hyperthermia
Study: 7574814
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy alone
Study: 387498
Drug: Oral trithiozine
Normalized name: anethole trithione
DrugBank: Anethole trithione (DB13853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trithiozine
Study: 26514065
Drug: Short-term psychodynamic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychodynamic group therapy (20 weekly sessions)
Study: 26514065
Drug: Long-term psychodynamic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term psychodynamic group therapy (80 weekly sessions)
Study: 21369479
Drug: HA/CMC injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA/CMC injection
Study: 15475635
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hepatitis B vaccine (2 mcg) given intradermally
Study: 15475635
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose hepatitis B vaccine (10 mcg) given intramuscularly
Study: 7577849
Drug: Gestrinone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone (2.5 mg twice weekly)
Study: 20211501
Drug: Multidimensional exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional exercise (twice a week for 3 months)
Study: 17962426
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of 150 mg lamivudine, 300 mg zidovudine, and 200 mg nevirapine
Study: 17962426
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination and individual products
Study: 11211891
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b 3 MU tiw for 24 or 48 weeks plus ribavirin 1000‐1200 mg
Study: 9510317
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg mesalazine suppositories administered three times per day